HGH Frag (176-191)
Price range: 64,00 € through 116,00 €
HGH Frag (176-191) - Targeted Fat Loss & Metabolic Activation
Description
HGH Frag (176-191) represents the C-terminal 15-amino-acid sequence of the full-length human growth hormone (HGH) molecule. This segment is responsible for fat metabolism modulation, retaining the potent lipolytic action of native HGH while eliminating its proliferative and insulin-antagonistic effects. Researchers have focused on this fragment for its specificity toward adipose tissue, making it a central molecule in studies of energy regulation and weight management.
The peptide functions through enhancement of beta-adrenergic lipolytic signaling and suppression of new fat cell formation (lipogenesis). By binding to a unique receptor subset distinct from classical growth hormone receptors, HGH Frag initiates a cascade of cAMP-dependent enzyme activations that promote fat oxidation and energy release.
Formulated in a stabilized pre-mixed injection pen for SubQ administration, HGH Frag (176-191) offers high bioavailability and accurate dosing for research environments, reducing degradation and ensuring consistent pharmacokinetic behavior.
Clinical Status:
HGH Frag (176-191) remains a research-only peptide with preclinical and limited human trial data supporting its lipolytic activity.
Evidence type:
Human RCT ☐ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
The fragment interacts with adipocyte surface receptors linked to adenylate cyclase, increasing intracellular cAMP levels and activating protein kinase A (PKA). This enzymatic cascade stimulates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), accelerating triglyceride hydrolysis and fatty acid release. Concurrently, it downregulates lipogenic enzymes such as acetyl-CoA carboxylase (ACC), reducing lipid storage. Unlike full-length HGH, HGH Frag does not induce IGF-1 expression, minimizing anabolic or diabetogenic activity.
Benefits
- Targeted Fat Metabolism Without Growth Effects:
HGH Frag (176-191) is a synthetic peptide fragment of human growth hormone designed to selectively activate fat-burning pathways without stimulating overall growth or insulin resistance. It represents the lipolytic domain of the HGH molecule and is studied for its ability to promote efficient fat metabolism while avoiding the systemic hormonal effects of full-length HGH. - Enhanced Lipolysis and Reduction of Adipose Tissue:
Research demonstrates that HGH Frag (176-191) significantly increases lipolysis and fatty acid oxidation in adipose cells. By stimulating hormone-sensitive lipase and inhibiting lipogenesis, it reduces stored fat, particularly in stubborn regions such as the abdomen. These effects have made it a central focus in metabolic and obesity-related peptide studies. - Improved Fat Utilization and Energy Efficiency:
In preclinical and clinical research, HGH Frag enhances fat mobilization for energy production while maintaining glucose homeostasis. This shift in substrate preference toward lipid oxidation supports overall metabolic efficiency and energy balance, distinguishing it from traditional weight loss interventions that often compromise muscle tissue. - Preservation of Lean Muscle Mass:
Unlike full-length HGH, this peptide fragment does not promote insulin resistance or excessive IGF-1 stimulation, allowing fat reduction without muscle catabolism. Research indicates that HGH Frag (176-191) helps preserve lean body mass even during caloric restriction, supporting favorable body composition outcomes in experimental protocols. - Improvement of Lipid and Glucose Regulation:
HGH Frag has been observed to improve lipid metabolism and insulin sensitivity by promoting fatty acid oxidation and reducing circulating triglycerides. It does not interfere with carbohydrate metabolism, which allows stable glucose levels throughout the research period, highlighting its safety and selectivity compared to full-length somatropin. - Localized Fat Reduction Potential:
Preclinical data suggest that HGH Frag (176-191) may exert region-specific fat loss effects due to localized receptor activation. This has led to ongoing research on targeted administration protocols to influence stubborn fat areas, providing insights into site-specific lipolytic modulation mechanisms. - Improved Mitochondrial Activity and Energy Expenditure:
Studies indicate that HGH Frag increases mitochondrial fatty acid oxidation, supporting enhanced ATP production and thermogenic activity. This improvement in mitochondrial efficiency underlies its observed effects on sustained energy expenditure, making it a promising candidate for metabolic rate optimization research. - No Impact on Growth or Proliferative Pathways:
Unlike native HGH, this peptide fragment does not activate pro-growth or mitogenic signaling pathways. It does not elevate IGF-1 levels or stimulate cell proliferation, resulting in a safer metabolic profile for long-term experimental use focused purely on fat metabolism and energy balance. - Support for Weight Management and Body Recomposition:
Due to its ability to target fat reduction while preserving lean tissue, HGH Frag (176-191) is commonly included in research focusing on body recomposition, metabolic flexibility, and adipose regulation. Its selective action provides an effective model for studying sustained weight management mechanisms without endocrine disruption. - Synergistic Potential with Metabolic and Recovery Peptides:
HGH Frag (176-191) is frequently studied in combination with AOD-9604, CJC-1295, or Ipamorelin to enhance lipolytic, regenerative, and anabolic outcomes. These experimental stacks explore synergistic pathways that optimize fat oxidation, hormonal balance, and recovery potential in performance and longevity research. - Favorable Safety Profile and Non-Mitogenic Nature:
Extensive preclinical testing shows that HGH Frag (176-191) maintains a favorable safety profile with no proliferative effects on bone or organ tissue. Its specificity for fat metabolism makes it a preferred choice in experimental studies aiming for targeted lipolysis without systemic growth factor stimulation.
Research Data
| Study/model | Reported effect |
| Animal models (obese mice) |
↓ total body fat by 50% within 4 weeks; ↑ lipolysis without changes in IGF-1
|
| In vitro adipocyte studies |
↑ cAMP and activation of hormone-sensitive lipase; ↓ triglyceride synthesis
|
| Human observational studies |
↓ abdominal fat thickness and improved skinfold measurements
|
| High-fat diet rodent models |
↓ visceral adipose tissue and plasma triglycerides
|
| Comparative studies (vs HGH) |
Equivalent fat-burning efficacy with reduced side effects
|
| Cell culture mitochondrial assays |
↑ β-oxidation enzyme expression and oxygen consumption rate
|
| Preclinical tolerance tests |
No influence on glucose or insulin levels; no water retention observed
|
Stack Suggestions
- Often combined with IGF-1 LR3 for muscle preservation during fat loss
- Stacked with BPC-157 for tissue recovery after rapid recomposition
- NAD+ for cellular energy synergy
Caution: Stacks discussed are for experimental design not safety/efficacy guidance.
Pen Dosage Chart
| HGH Frag (176-191) Pen 5 mg | |
| Volume | 2.0 mL |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 10 clicks = 0.25 mg; 50 clicks = 1.25 mg |
| HGH Frag (176-191) Pen 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.50 mg; 50 clicks = 2.5 mg |
| HGH Frag (176-191) Pen 15 mg | |
| Volume | 3.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.50 mg; 50 clicks = 2.5 mg |
Dosage & Protocols Variations
Standard Research Protocol
- Dose: 0.25 – 0.5 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 4-week rest
- Goal / Description: Commonly studied for its fat-reducing effects and metabolic activity
Split Dose Protocol
- Dose: 0.25 mg AM + 0.25 mg PM
- Duration: 8 – 12 weeks
- Frequency: 2× daily
- Cycle Interval: 4-week rest
- Goal / Description: Divided dosing enhances lipolytic rhythm throughout the day
High-Intensity Fat Loss Protocol
- Dose: 0.5 – 1 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily (pre-meal)
- Cycle Interval: 8-week rest
- Goal / Description: Investigated in advanced metabolic models targeting visceral fat
Possible Side Effects
HGH Frag (176-191), as a research peptide focused on lipolysis, may induce mild side effects in experimental models, mainly localized or transient. These are dose-related and more notable at higher levels. Close monitoring is advised for subcutaneous delivery.
Injection Site Reactions: Redness, swelling, or itching at the site, resolving within hours. Rotating areas reduces this.
Headache: Mild, possibly from vascular changes or rapid fat mobilization.
Nausea: Occasional queasiness, linked to metabolic shifts early on.
Fatigue: Transient lethargy, due to energy redirection.
Increased Heart Rate: Slight tachycardia in sensitive models, attributed to adrenergic activation.
Most side effects are minor and manageable via dose adjustment. Limited data suggest no long-term risks like insulin disruption, though vigilance for hypersensitivity is recommended.
Product Attributes
- CAS #: 221231-10-3
- Molecular Formula: C78H123N23O23S2
- Sequence (AA): 16 amino acids (176-191 fragment of hGH)
- Molecular Weight: ~1,817 g/mol
- PubChem CID: 16126616
- Half-Life: ~2 – 3 hours
- Synonyms: HGH Fragment, GH Frag, Growth Hormone Fragment 176-191, AOD9604
- Type: Synthetic peptide fragment of human growth hormone
- Research Focus: Weight Loss & Metabolic Function
Scientific References
- Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells In vitro
- Detection and in vitro metabolism of AOD9604 In vitro
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Animal
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Animal
- Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604 Observational
- Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model Animal
- Obesity drugs in clinical development Review
- Effects of oral administration of synthetic fragment of human growth hormone on lipid metabolism Animal
- Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells In vitro
- Fragment 176-191 peptide and studies in weight Review
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 7°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS cold-chain transport boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not support merchants in this field.
For this reason, we accept bank transfers only.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day (cut-off dependent).
This method ensures compliance, security, and continuity of service for all customers across the EU.
